FierceBiotech 13. Apr. 2026 BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types
FierceBiotech 28. Feb. 2026 BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival